TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03906162

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Base intervention
Description: The base intervention consists of a physical activity monitor (PAM) for everyday use in the intervention period and a pamphlet with information about Danish recommendations on physical activity in aging populations. The PAM will be the Garmin Vivofit 3 monitor linked to a pre-specified Garmin Connect account. The participants will be asked to install the Garmin Connect application on their smartphone and use the given ID/password in the app. The participants will be asked to wear the monitor 24-hours a day for the 12-week intervention period. The participants can use the PAM as they like but they will be asked to try to use the PAM and the application to enhance their daily level of physical activity.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Base intervention
Description: The base intervention consists of a physical activity monitor (PAM) for everyday use in the intervention period and a pamphlet with information about Danish recommendations on physical activity in aging populations. The PAM will be the Garmin Vivofit 3 monitor linked to a pre-specified Garmin Connect account. The participants will be asked to install the Garmin Connect application on their smartphone and use the given ID/password in the app. The participants will be asked to wear the monitor 24-hours a day for the 12-week intervention period. The participants can use the PAM as they like but they will be asked to try to use the PAM and the application to enhance their daily level of physical activity.
Study: NCT02963311

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALN-PCSSC
Description: ALN-PCSSC is a small interfering ribonucleic acid (siRNA) that inhibits PCSK9 synthesis and is given as SC injections.
Study: NCT00014911

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Administered at a dose of 1 mg by mouth once pre-transplantation followed by 1 mg twice daily post transplantation. Levels will be adjusted to achieve a peripheral blood trough level of 3-6 ng/mL for maintenance immunosuppression.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daclizumab
Description: Administered at a dose of 1 mg/kg intravenously immediately pre-transplantation and 2, 4, 6, and 8 weeks post-transplantation, totaling 5 doses(over 8 weeks). Further daclizumab dosing may be necessary based on individual results and islet transplantation needs.
Study: NCT02963311

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Included maximally-tolerated statin therapy and/or other low density lipoprotein-cholesterol (LDL-C)-lowering therapies.
Study: NCT02902783

Intervention type: OTHER
Intervention: Data Collection
Description: Data collection relevant to this study will be obtained by observation and review of hospital charts. Limited data will be obtained through relevant organ donation organizations (ODOs).
Study: NCT00014911

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulfamethoxazole
Description: An antibacterial used to prevent opportunistic infections
Study: NCT03829696

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mifeprex® (Mifepristone 200 mg)
Description: Participants will receive Mifeprex® (mifepristone 800 mcg) from a clinician when they are not pregnant. Participants who have an unintended pregnancy during the study period and would like to have a medication abortion will consult with a clinician for an over-the-phone evaluation of contraindications and gestational age. Participants who take the medications will be evaluated again in-person at a subsequent follow-up visit.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol 800 mcg
Description: Participants will receive misoprostol from a clinician when they are not pregnant. Participants who have an unintended pregnancy during the study period would like to have a medication abortion will consult with a clinician for an over-the-phone evaluation of contraindications and gestational age. Participants who take the medications will be evaluated again in-person at a subsequent follow-up visit.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ella® (ulipristal acetate emergency contraception 30 mg)
Description: Participants will receive one dose of ella (emergency contraception) from a clinician at the same time of receiving mifepristone and misoprostol, in case the participant should have unprotected intercourse or failed contraception and want to prevent unintended pregnancy.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: AccuHome® Pregnancy OTC Test
Description: Participants will receive 6 AccuHome® pregnancy tests, which are midstream urine pregnancy tests and provide results within 3 minutes. Participants may request additional tests to be mailed to them by the study at any time.
Study: NCT01195103

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fospropofol disodium
Description: 10 mg/kg bolus

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fospropofol disodium
Description: 6.5 mg/kg bolus

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo + Midazolam
Description: Placebo bolus plus midazolam. The dose of midazolam will be based on the patient's weight: 1 mg for patients \<60 kg; 1.5 mg for patients ≥60 kg to \<90 kg; or 2 mg for patients ≥90 kg
Study: NCT04286152

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirabegron 50 MG
Description: The experimental drug is administered to patients PO once a day for 7 days from stent insertion until removal

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: A sugar pill manufactured to mimic Mirabegron 50 mg tablet is administered to patients PO once a day for 7 days from stent insertion until removal
Study: NCT00355030

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: somatropin
Description: 0.05 mg/kg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: somatropin
Description: 0.05 mg/kg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leuprorelin
Description: 11.25 mg/3 months
Study: NCT02343848

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: smart bracelet.
Description: Physical activity will be evaluated using smart bracelet.
Study: NCT02415088

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Interscalene block
Description: block of the plexus brachialis in the interscalene region with local anaesthetics
Study: NCT01602263

Intervention type: PROCEDURE
Intervention: Transcranial Direct Current Stimulation (tDCS)
Description: Anodal, Cathodal or Sham tDCS.

Intervention type: PROCEDURE
Intervention: Transcranial Direct Current Stimulation (tDCS)
Description: Anodal, Cathodal or Sham tDCS.

Intervention type: PROCEDURE
Intervention: Transcranial Direct Current Stimulation (tDCS)
Description: Anodal, Cathodal or Sham tDCS.

Intervention type: PROCEDURE
Intervention: Transcranial Direct Current Stimulation (tDCS)
Description: Anodal, Cathodal or Sham tDCS.
Study: NCT04240886

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fosmanogepix
Description: IV and oral fosmanogepix

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fosmanogepix
Description: IV and oral fosmanogepix
Study: NCT01462929

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aclidinium bromide
Description: Dosage form: Dry powder. Route of administration: Oral inhalation by Genuair multidose dry powder inhaler Dose and regimen: 1 puff of 400 micrograms in the morning (09:00 ± 1h) and in the evening (21:00 ± 1h)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tiotropium
Description: Dosage form: Dry powder hard gelatin capsule. Route of administration: Oral inhalation by HandiHaler single-dose dry powder inhaler Dose and regimen: 1 capsule (18 μg) in the morning (09:00 ± 1h)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dosage form: Dry powder Route of administration: Oral inhalation by Genuair multidose dry powder inhaler. 1 puff of placebo in the morning (09:00 ± 1h) and 1 puff in the evening (21:00 ± 1h) AND Oral inhalation by HandiHaler single-dose dry powder inhaler. 1 puff of placebo in the morning (09:00 ± 1h).
Study: NCT01673776

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PulsioFlex® Monitoring
Description: * goal directed therapy according to PulsioFlex® Monitoring- measurements~* femoral catheter~* extended perioperative monitoring~* nutritional supplementation, (if necessary)
Study: NCT04032886

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: kinesio tape
Description: This is a taping method used for correction of rounded shoulders.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: kinesio tape
Description: This is a taping method used for correction of rounded shoulders.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise
Description: Exercises include basic postural exercises.

Intervention type: OTHER
Group type: OTHER
Intervention: exercise
Description: Exercises include basic postural exercises.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise
Description: Exercises include basic postural exercises.
Study: NCT01195103

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: All patients will receive a single dose of IV fentanyl (approximately 1 μg/kg not to exceed: 50 μg for patients \<60 kg; 75 μg for patients ≥90 kg) five minutes prior to the initial dose of sedative.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: All patients will receive a single dose of IV fentanyl (approximately 1 μg/kg not to exceed: 50 μg for patients \<60 kg; 75 μg for patients ≥90 kg) five minutes prior to the initial dose of sedative.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: All patients will receive a single dose of IV fentanyl (approximately 1 μg/kg not to exceed: 50 μg for patients \<60 kg; 75 μg for patients ≥90 kg) five minutes prior to the initial dose of sedative.
Study: NCT02536326

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LEPU Renal Denervation System
Description: LEPU Renal denervation system was similar to Symplicity Catheter System (Medtronic Inc.)
Study: NCT01612026

Intervention type: PROCEDURE
Intervention: arterial cannulation by angiographic imaging
Description: comparing successful arterial cannulation in case of non-cardiac vascular patient population.

Intervention type: PROCEDURE
Intervention: arterial cannulation by angiographic imaging
Description: comparing successful arterial cannulation in case of non-cardiac vascular patient population.
Study: NCT01024686

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: p52-/p36- GAP Vaccine
Description: Administered by five bites from GAP-infected Anopheles mosquito

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: p52-p36- GAP Vaccine
Description: Administered by 200 bites from GAP-infected Anopeles mosquito

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: p52-/p36- GAP Vaccine
Description: Five doses separated by 4-weeks, each administered by 200 bites from GAP-infected Anopheles mosquito
Study: NCT04614623

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AHCL pump
Description: Advanced Hybrid Closed Loop (AHCL) pump automatically adjusts insulin infusion rate of pump customized to patient's needs to reduce occurrence of hypo and hyperglycemia

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AHCL pump
Description: Advanced Hybrid Closed Loop (AHCL) pump automatically adjusts insulin infusion rate of pump customized to patient's needs to reduce occurrence of hypo and hyperglycemia

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video conferencing Application
Description: Video conferencing application will be used to enhance communication between participant and parent with the study certified diabetes educator (CDE) nurse coordinator. These individualized sessions will be designed to help the family with solving diabetes management problems to enhance glycemic control

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video conferencing Application
Description: Video conferencing application will be used to enhance communication between participant and parent with the study certified diabetes educator (CDE) nurse coordinator. These individualized sessions will be designed to help the family with solving diabetes management problems to enhance glycemic control
Study: NCT00361335

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Golimumab
Description: 2mg/kg or 4mg/kg will be administered as an IV infusion over 30 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Golimumab
Description: 2mg/kg or 4mg/kg will be administered as an IV infusion over 30 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Golimumab
Description: 2mg/kg or 4mg/kg will be administered as an IV infusion over 30 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Golimumab
Description: 2mg/kg or 4mg/kg will be administered as an IV infusion over 30 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Active MTX capsules, filled with microcrystalline cellulose (Avicel PH 102) and a 2.5 mg MTX tablet, will be administered at the same dose as before the study entry.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Active MTX capsules, filled with microcrystalline cellulose (Avicel PH 102) and a 2.5 mg MTX tablet, will be administered at the same dose as before the study entry.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methotrexate
Description: Active MTX capsules, filled with microcrystalline cellulose (Avicel PH 102) and a 2.5 mg MTX tablet, will be administered at the same dose as before the study entry.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo solution will be administered through IV infusion in Group V and oral placebo capsules (sham MTX) filled with microcrystalline cellulose (Avicel PH 102) will be administered in Group II and IV.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo solution will be administered through IV infusion in Group V and oral placebo capsules (sham MTX) filled with microcrystalline cellulose (Avicel PH 102) will be administered in Group II and IV.
Study: NCT03449849

Intervention type: OTHER
Group type: OTHER
Intervention: Base Diet
Description: Base Diet
Study: NCT02914119

Intervention type: DRUG
Intervention: Rocuronium

Intervention type: DRUG
Intervention: Succinylcholine

Intervention type: DRUG
Intervention: Cisatracurium

Intervention type: DRUG
Intervention: Mivacurium

Intervention type: DEVICE
Intervention: Objective neuromuscular monitoring (acceleromyography)

Intervention type: DRUG
Intervention: Sugammadex

Intervention type: DRUG
Intervention: Neostigmine
Study: NCT03449849

Intervention type: OTHER
Group type: OTHER
Intervention: Kale Treatment
Description: Base Diet plus Kale
Study: NCT02515344

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Providing a list of patients not compliant with CRC sreening
Description: GPs allocated to the intervention group (A) will receive a list of the patients who are not compliant to colorectal cancer screening, while GPs allocated to the others groups will not receive this information.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Providing general information about CRC sreening

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Providing general information about CRC sreening
Study: NCT02895516

Intervention type: DEVICE
Group type: OTHER
Intervention: Vibrating capsule
Description: Patients will receive vibrating capsule for 6 weeks of treatment (2 capsules per week)
Study: NCT00014911

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ganciclovir
Description: An antiviral used to kill viruses and stop viral replication

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trimethoprim
Description: An antibacterial used to prevent opportunistic infections

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentamidine
Description: An antiprotozoal used to prevent disease
Study: NCT03336190

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: avatar-based training
Description: Interaction with an avatar-based module to practice skills learned during the toolkit training
Study: NCT02675725

Intervention type: DEVICE
Intervention: Measurement of sublingual microcirculation with Cytocam-IDF camera
Description: The normal treatment of a post-cardiac surgery patient is fluid bolus by indication. This indications are hypotension, hyperlactataemia, tachycardia or decreased urine production. This fluid bolus is 250 ml crystalloids in 15 minutes.~When this fluid bolus will be given, the investigators will observe the sublingual microcirculation and measure the red blood cell velocity and total vessel density on one spot for 20 minutes.
Study: NCT01057134

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cutera Ultrasound Device
Description: Pulse duration 10-100 ms, fluence greater or equal to 50 J/cm2, contact tip temperature 5-30 celsus, frequency 5-20 MHz.
Study: NCT01962688

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Handheld ultrasound
Description: Handheld ultrasound determination of IVC diameter
Study: NCT04230967

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ambulation Group
Description: Participants in the ambulation arm will be allowed ad lib activity and instructed that they should walk at least once per day out of their room with a goal of 2,000 steps per day. The Fitbit Inspire devices will be set to this goal and notifications will be given on the device for the participants meeting their goals

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Routine Care
Description: No encouragement to ambulate will be provided to subjects. Their movement will be recorded
Study: NCT02377024

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: TF 600mg

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: TF 1200mg

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT01962688

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Handheld ultrasound
Description: Handheld ultrasound determination of IVC diameter

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham ultrasound
Description: sham ultrasound to facilitate blinding

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham ultrasound
Description: sham ultrasound to facilitate blinding
Study: NCT02882737

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucagon before exercise

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucagon after exercise

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucagon after resting
Study: NCT01231607

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1mg Finasteride active
Description: 1mg finasteride active, by mouth once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.02mg dutasteride
Description: 0.02mg dutasteride active, by mouth once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.1mg dutasteride
Description: 0.1mg dutasteride active, by mouth once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.5mg dutasteride
Description: 0.5mg dutasteride active, by mouth once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Finasteride placebo
Description: finasteride placebo, by mouth once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Finasteride placebo
Description: finasteride placebo, by mouth once daily
Study: NCT00361335

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo solution will be administered through IV infusion in Group V and oral placebo capsules (sham MTX) filled with microcrystalline cellulose (Avicel PH 102) will be administered in Group II and IV.
Study: NCT00536263

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pegylated interferon alpha-2b
Description: 1.0 mcg/kg subcutaneously (S.C.) QW for 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegylated interferon alpha-2b
Description: 1.5 mcg/kg S.C. QW for 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegylated interferon alpha-2b
Description: 1.5 mcg/kg S.C. QW for 48 weeks
Study: NCT03061682

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Scharioth macula lens A45sml/A45smy
Description: Implantation of an add on intraocular lens to low vision patients
Study: NCT01231607

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Finasteride placebo
Description: finasteride placebo, by mouth once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Finasteride placebo
Description: finasteride placebo, by mouth once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dutasteride placebo
Description: dutasteride placebo, by mouth once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dutasteride placebo
Description: dutasteride placebo, by mouth once daily
Study: NCT01203787

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib Standard Dosing Regimen
Description: Sorafenib 400 mg twice daily until wk 24 or end of treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sorafenib Ramp-Up Regimen
Description: 200 mg daily, Day 0-Day 13 200 mg twice daily, Day 14-Day 20 600 mg daily, Day 21-Day 27 400 mg twice daily, Day 28 until end of treatment400 mg twice daily
Study: NCT03129633

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention group
Description: One-on-one contact with a promotor(a) over the 6 month intervention.
Study: NCT05594433

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenograstim
Description: Injection sub cutaneous of Lenograstim during 4 days, once per day
Study: NCT04527276

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oral care with 0,12% Chlorhexidine
Description: 0, 12 % CHX, and standard oral care with 0,9% NaCl were compared to assess VAP rates. Both solutions were applied to critically ill children who were intubated.
Study: NCT03620435

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab (1200mg iv, every 3 weeks) administered concurrently with TMT and adjuvant for up to one year